SCHEMBL11921938

CO[C@H]1OC(CO)[C@@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3OC(COS(=O)(=O)O)[C@H](O[C@H]4C[C@H](O)[C@H](O[C@H]5OC(COS(=O)(=O)O)[C@@H](O[C@H]6C[C@H](O)[C@H](O[C@@H]7OC(COS(=O)(=O)O)[C@H](O[C@H]8C[C@H](O)[C@H](O)CO8)[C@H](O)C7N)CO6)[C@H](O)C5N)CO4)[C@H](O)C3N)CO2)[C@H](O)C1N

nearest known ligand 0.38

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	BLM	P54132	1/20	0.38

▸	RECQL	P46063	1/20	0.38

▸	TDP1	Q9NUW8	1/20	0.38

▸	FGF1	P05230	3/20	0.37

▸	MEN1	O00255	1/20	0.34

▸	LRAT	O95237	1/20	0.34

▸	TRPV1	Q8NER1	1/20	0.34

▸	GAA	P10253	1/20	0.33

▸	HSD17B10	Q99714	1/20	0.33

▸	TSHR	P16473	1/20	0.33

▸	MAPT	P10636	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL16656556	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11921942	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11997482	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11921923	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11997485	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11997483	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11997478	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11921934	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11997469	1.00	BLM (0.38)	BLMRECQLTDP1FGF1MEN1
SCHEMBL11997463	0.96	FGF1 (0.35)	BLMRECQLTDP1FGF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9527930-B2	FGF receptor-activating N-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof	SANOFI (FR)	2016-12-27	—	—	US	disclosed
US-20120202769-A1	FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	SANOFI (FR)	2012-08-09	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120202769-A1	FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	FGFR1, FGF1, FGF2	BLM 4746/4885RECQL 3828/4885TDP1 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.